All News

A small study conducted in Melbourne, Australia, found that older age and being from a culturally and linguistically diverse community were associated with less awareness of pulmonary rehabilitation among patients with chronic obstructive pulmonary disease (COPD).

Mitigating the high cost of prescription drugs is a win-win to address the complex, multipronged problem of getting patients to take their medications as advised.

Two abstracts presented at the 2022 American Academy of Dermatology (AAD) Annual Meeting explored the health-related quality of life (QOL) and mental health impact of psoriasis disease burden by severity and affected body region.

With more people living with HIV now reaching advanced ages and qualifying for Medicare coverage, this new study investigated HIV-related influences on their health care spending, particularly antiretroviral therapy (ART), compared with a population who does not have HIV.

New research published in Health Affairs details the rates of specialty medication noninitiation among Medicare Part D beneficiaries.

Patients hospitalized for acute heart failure and prescribed empagliflozin saw improvements in quality of life at 15 and 90 days post-discharge. The study may make the case for prescribing SGLT2 inhibitors before patients leave the hospital.

Researchers presented new data on patient characteristics and outcomes seen in the VICTORIA trial of vericiguat.

Norman E. “Ned” Sharpless, MD, is departing shortly after the launch of Cancer Moonshot 2.0, an initiative that aims to reduce the cancer death rate by at least half over the next 25 years while improving the experience for all those affected by cancer.

Melissa Johnson, MD, program director of Lung Cancer Research at Sarah Cannon, discusses the need for increased lung cancer screening among patients who have no tobacco use history.

A review expanded on urological complications associated with Parkinson disease (PD), as well as therapies for these complications.

Immune checkpoint inhibitors have changed the treatment landscape of certain cancer types, and a recent study aims to provide new insight on why treatment response varies so much from patient to patient.

Debra Patt, MD, PhD, MBA, executive vice president of Texas Oncology, explains recommendations for annual mammography screenings after COVID-19 vaccination and why guidelines differ for diagnostic visits.

Many oncologists oppose white bagging because they prefer to be able to adjust doses during a visit based on lab reports taken that day.

Of 5 RNA investigated, 2 correlated with systemic lupus erythematosus and the last correlated with certain inflammation-related symptoms.

Experts outlined updates in the use of artificial intelligence, wearable devices, and artificial wombs for cardiac health during a session at the American College of Cardiology (ACC)’s 71st Scientific Sessions.

Ryan Haumschild, PharmD, MS, MBA, director of pharmacy services at Emory Healthcare and Winship Cancer Institute, explains how payers can play an essential role in improving biosimilar adoption.

William Schaffner, MD, medical director at the National Foundation for Infectious Diseases (NFID), and Patsy Stinchfield, RN, MS, CPNP, president-elect of NFID, discuss health care disparities related to respiratory syncytial virus (RSV), as well as solutions to close these gaps.

The new guidelines also call for better incorporation and addressing of social determinants of health.

Because type 1 diabetes can be very difficult to effectively manage in children and adolescents, these study investigators compared outcomes between a hybrid closed-loop algorithm add-on and usual care.

A child’s schooling is affected by the impact of eosinophilic esophagitis (EoE), explained Colette Romero, whose son has the disease.

Whether a patient is refractory to initial treatment dictates the future course of care.

A significantly greater proportion of patients with chronic rhinosinusitis with nasal polyps reported symptom-free days for at least 1 symptom when treated with dupilumab vs placebo in the 28 days preceding 24-week and 52-week analysis intervals.

Additional analyses from the SCORED trial further highlight sotagliflozin's benefits among patients with type 2 diabetes and chronic kidney disease, regardless of cardiovascular disease presence.

Only half of pediatric patients with atopic dermatitis who fit the criteria of having severe disease were identified as such by managing physicians.

Data underscored the efficacy of mavacamten in reducing eligibility for surgical intervention among patients with obstructive hypertrophic cardiomyopathy (oHCM).

Attending comprehensive sexuality education (CSE) was associated with increased access to HIV testing among adolescent girls, regardless of whether they were actively in school.

Milind Desai, MD, MBA, director of the Center for Hypertrophic Cardiomyopathy and medical director of the Center for Aortic Diseases, Cleveland Clinic, speaks on therapeutic implications of the VALOR-HCM late-breaking clinical trial findings presented Saturday at the American College of Cardiology's 71st Scientific Session.

Christopher Phillips, MD, a rheumatologist in Kentucky, discusses the back-and-forth that providers have with insurers in trying to get therapies approved for reimbursement.